Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Innate Pharma Highlights Early Lacutamab Data In Aggressive Form Of Blood Cancer

Published 12/12/2022, 16:35
Updated 12/12/2022, 17:40
© Reuters. Innate Pharma Highlights Early Lacutamab Data In Aggressive Form Of Blood Cancer
IPH
-

Benzinga -

  • Innate Pharma SA (NASDAQ: IPHA) presented data from a preliminary analysis of the TELLOMAK Phase 2 trial demonstrating clinical activity and a favorable safety profile for lacutamab in patients with advanced Sézary syndrome, a form of T cell lymphoma.
  • At the time of data cut-off (April 29, 2022), the Intention To Treat (ITT1) population included 37 post-mogamulizumab patients, and 35 patients were Evaluable for Efficacy (EES2).
  • Related: AstraZeneca (NASDAQ:AZN) Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer.
  • The global objective response rate (ORR) in the ITT population was 21.6% (8/37). ORR in the blood was 37.8%, with 21.6% (8/37) achieving complete response (CR). ORR in the skin was 35.1%.
  • In the EES population, global ORR was 22.9% (8/35). ORR in the blood was 40.0%, and ORR in the skin was 37.1%.
  • In line with previous observations, lacutamab demonstrated a favorable safety profile.
  • Grade ≥ 3 Treatment-related (TR) Treatment-Emergent Adverse events (TEAEs) were observed in 6/37 (16.2%) patients.
  • Price Action: IPHA shares are up 4.72% at $2.22 on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.